Home > Rheumatology > ACR 2021 > Late-Breaking Posters > Promising results in uric acid-lowering in gout patients with a new xanthine oxidase inhibitor

Promising results in uric acid-lowering in gout patients with a new xanthine oxidase inhibitor

Presented By
Prof. Robert Terkeltaub, University of California San Diego, CA, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ACR 2021
Trial
Phase 2
Demonstrating efficacious serum urate-lowering in gout patients with hyperuricemia, tigulixostat is now predestined for further development. No particular safety signals were reported and overall drug tolerance was good in new phase 2 results. In the effective management of gout, keeping the level of serum uric acid below its limit of solubility is key, but a substantial part of patients does not reach this therapeutic goal [1,2]. “Tigulixostat is a novel selective xanthine oxidase inhibitor and, unlike allopurinol, it does not have a purine-like backbone structure,” Prof. Robert Terkeltaub (University of California San Diego, CA, USA) described the new agent. A phase 2 study (NCT03934099) investigated tigulixostat for safety and efficacy in patients with gout and hyperuricemia [1]. The study population consisted of 156 patients with gout, who were randomise...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on